CR
CRSP.US Crispr Therapeutics AG
- Market cap
- USD 4.10B
- P/E
- -
- P/B
- 2.51x
- ROE
- -26.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRSP.US undervalued?
Graham numberThe Graham number of Crispr Therapeutics AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Crispr Therapeutics AG fundamental analysis
No fundamental analysis for Crispr Therapeutics AG yet.
Crispr Therapeutics AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathi…
Full company profileCrispr Therapeutics AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Crispr Therapeutics AG annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.16M | 41.0M | 3.12M | 290M | 719K | 913M | 436K | 370M | 35.0M | 3.51M | 32.4M |
| Gross Profit | -37.1M | -28.8M | 3.12M | 290M | -269M | 913M | -110M | 240M | -75.3M | -229M | -149M |
| Operating Income | -68.1M | -64.6M | -159M | 46.7M | -354M | 374M | -673M | -223M | -467M | -568M | -500M |
| EBITDA | -13.7M | -61.6M | -155M | 51.5M | -345M | 391M | -649M | -131M | -343M | -558M | -447M |
| Net Income | -23.2M | -68.4M | -165M | 66.9M | -349M | 378M | -650M | -154M | -366M | -582M | -434M |
| EPS | -1.89 | -1.71 | -3.44 | 1.17 | -5.29 | 4.70 | -8.36 | -1.94 | -4.34 | -6.47 | -4.49 |
| Balance Sheet | |||||||||||
| Total Assets | 345M | 271M | 489M | 1.07B | 1.83B | 2.75B | 2.24B | 2.23B | 2.24B | 2.27B | 2.56B |
| Total Liabilities | 112M | 83.5M | 96.8M | 127M | 164M | 352M | 368M | 347M | 310M | 343M | 908M |
| Shareholders' Equity | 233M | 188M | 392M | 939M | 1.66B | 2.40B | 1.88B | 1.88B | 1.93B | 1.92B | 1.65B |
| Cash & Short-term Investments | 316M | 240M | 457M | 944M | 1.69B | 2.38B | 1.82B | 1.69B | 1.90B | 1.98B | 2.27B |
| Total Debt | - | - | - | 52.5M | 61.4M | 225M | 244M | 239M | 224M | 395M | 780M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -55.3M | -70.1M | -96.2M | 56.7M | -238M | 539M | -496M | -260M | -143M | -345M | -376M |
| Capital Expenditure | 3.02M | 7.81M | 2.77M | 6.68M | 18.4M | 81.7M | 37.2M | 9.47M | 1.90M | 914K | 5.39M |
| Free Cash Flow | -58.3M | -77.9M | -99.0M | 50.0M | -257M | 457M | -533M | -270M | -145M | -346M | -381M |
| Ratios | |||||||||||
| ROE | -10.0% | -36.4% | -42.1% | 7.1% | -21.0% | 15.7% | -34.7% | -8.2% | -19.0% | -30.3% | -26.3% |
| ROA | -6.7% | -25.2% | -33.7% | 6.3% | -19.1% | 13.7% | -29.0% | -6.9% | -16.3% | -25.7% | -17.0% |
| Net Profit Margin | -449.3% | -166.7% | -5,281.1% | 23.1% | -48,520.9% | 41.4% | -149,122.7% | -41.5% | -1,046.4% | -16,569.8% | -1,339.2% |
| Debt to Equity | - | - | - | 0.06x | 0.04x | 0.09x | 0.13x | 0.13x | 0.12x | 0.21x | 0.47x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Crispr Therapeutics AG dividends
Crispr Therapeutics AG has not paid dividends in the last 9 fiscal years.
Last stock split: 333333:100000 on Jul 19, 2016.
Who owns Crispr Therapeutics AG
- Insiders 6.01%
- Institutions 79.18%
- Public & others 14.81%
- Shares outstanding 97.0M
- Free float 96.5M
Top funds holding CRSP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Innovation ETF | 5.35M | 5.51% | -3.15% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.91M | 3.00% | +2.68% | Oct 2026 |
| ARK Genomic Revolution ETF | 2.30M | 2.37% | +0.58% | Oct 2026 |
| iShares Russell 2000 ETF | 2.28M | 2.35% | 0.00% | Oct 2026 |
| American Funds New Perspective A | 1.94M | 2.00% | 0.00% | Sep 2026 |
| American Funds SMALLCAP World A | 1.69M | 1.75% | 0.00% | Sep 2026 |
| American Funds Growth Fd of Amer A | 1.41M | 1.46% | 0.00% | Sep 2026 |
| Orbis Global Equity Investor | 1.23M | 1.27% | 0.00% | Jun 2026 |
| Fidelity Small Cap Index | 1.02M | 1.05% | +0.13% | Aug 2026 |
| T. Rowe Price Mid-Cap Growth | 858K | 0.88% | -18.21% | Sep 2026 |
| Amova ARK Disruptive Innovation A USD | 846K | 0.87% | -3.82% | Sep 2026 |
| Orbis SICAV Global Bal Instl Inv | 838K | 0.86% | +2.40% | Mar 2026 |
| iShares Russell 2000 Value ETF | 732K | 0.75% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 698K | 0.72% | -0.49% | Oct 2026 |
| Fidelity Growth Company Fund | 592K | 0.61% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 523K | 0.54% | -2.46% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 513K | 0.53% | +0.24% | Oct 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 493K | 0.51% | -3.15% | Sep 2026 |
| Fidelity Extended Market Index | 448K | 0.46% | -5.40% | Sep 2026 |
| Orbis Optimal (US$) Fund | 384K | 0.40% | +12.02% | Mar 2026 |
Top institutions holding CRSP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Investment Management LLC | 9.46M | 9.75% | -16.38% | Jun 2026 |
| BlackRock Inc | 8.35M | 8.61% | +8.71% | Jun 2026 |
| Orbis Allan Gray Ltd | 5.45M | 5.62% | -10.76% | Jun 2026 |
| Capital World Investors | 4.75M | 4.90% | +0.52% | Jun 2026 |
| State Street Corp | 4.32M | 4.46% | +8.52% | Jun 2026 |
| GSK PLC | 3.22M | 3.32% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.51M | 2.59% | +5.58% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.05M | 2.12% | -30.47% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 2.04M | 2.10% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 1.99M | 2.05% | +34.09% | Jun 2026 |
| FMR Inc | 1.91M | 1.97% | -2.36% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 1.72M | 1.77% | -7.18% | Jun 2026 |
| Amova Asset Management Americas, Inc | 1.72M | 1.77% | -7.22% | Jun 2026 |
| EcoR1 Capital, LLC | 1.39M | 1.43% | 0.00% | Jun 2026 |
| UBS Group AG | 1.32M | 1.36% | -25.25% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 1.27M | 1.31% | +6.88% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.18M | 1.22% | +3.44% | Jun 2026 |
| Bank of America Corp | 1.16M | 1.19% | +17.50% | Jun 2026 |
| NEA Management Company, LLC | 1.06M | 1.09% | 0.00% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.06M | 1.09% | +1.78% | Jun 2026 |
Crispr Therapeutics AG company profile
- Company name
- Crispr Therapeutics AG
- Ticker
- CRSP.US
- ISIN
- CH0334081137
- Exchange
- USA Stocks
- Listed since
- Oct 19, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 393
- Fiscal year end
- December
- Address
- Baarerstrasse 14, Zug, Switzerland, 6300
- Phone
- 41 41 561 32 79
- Website
- crisprtx.com
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Crispr Therapeutics AG management
10- Dr. Samarth Kulkarni Ph.D.CEO & Chairman · born 1978
- Mr. James R. Kasinger J.D.General Counsel & Secretary · born 1972
- Dr. Raju Yashaswi Prasad Ph.D.Executive Officer · born 1984
- Dr. Naimish Patel C.M., M.D.Chief Medical Officer · born 1972
- Mr. Shaun Foy CFACo-Founder
- Dr. Emmanuelle Marie Charpentier Ph.D.Co-Founder & Scientific Advisory Board Member
- Dr. Craig C. Mello Ph.D.Scientific Founder & Advisory Board Member
- Dr. Chad A. Cowan Ph.D.Scientific Founder · born 1972
- Dr. Matthew Porteus M.D., Ph.D.Scientific Founder & Advisory Board Member · born 1965
- Dr. Daniel G. Anderson Ph.D.Scientific Founder & Advisory Board Member · born 1969